Related Articles
Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first‑line treatment of metastatic colorectal cancer
Cervical bone pain revealing a bone metastatic colon cancer: A case report
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer
Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first‑line treatment for Japanese patients with metastatic colorectal cancer
Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report